Neuropace Inc (NPCE)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $260.45M
Last updated: Nov 17, 2026 at 11:05 AM ET
Neuropace Inc (NPCE) Earnings: Report Dates and Results
Neuropace (NPCE) is expected to report earnings on Mar 1, 2027. In the quarter ended Sep 30, 2026, Neuropace reported EPS of -$0.10, above the -$0.14 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
NPCE has an expected report date of Mar 1, 2027.
NPCE Earnings Call
The latest NPCE earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 22 quarters below that had an estimate, NPCE beat 15, missed 6 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $23.10M, down 1.1% from $23.35M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.10 | -$0.14 | -$0.15 - -$0.05 | +28.57% | Beat | N/A | 8 | N/A | Nov 12, 2026 | $23.10M |
| Jun 30, 2026 | -$0.18 | -$0.19 | -$0.26 - -$0.15 | +5.26% | Beat | N/A | 8 | 2 up, 0 down | Aug 11, 2026 | $22.83M |
| Mar 31, 2026 | -$0.20 | -$0.23 | -$0.29 - -$0.18 | +13.59% | Beat | N/A | 6 | 3 up, 2 down | May 12, 2026 | $22.07M |
| Dec 31, 2025 | -$0.08 | -$0.15 | -$0.19 - -$0.10 | +46.67% | Beat | N/A | 7 | 4 up, 0 down | Mar 3, 2026 | $26.59M |
| Sep 30, 2025 | -$0.11 | -$0.19 | -$0.23 - -$0.16 | +42.11% | Beat | N/A | 7 | 3 up, 2 down | Nov 4, 2025 | $23.35M |
| Jun 30, 2025 | -$0.26 | -$0.22 | -$0.27 - -$0.17 | -18.18% | Miss | N/A | 7 | 4 up, 2 down | Aug 12, 2025 | $19.50M |
| Mar 31, 2025 | -$0.21 | -$0.24 | -$0.31 - -$0.17 | +12.50% | Beat | N/A | 6 | 4 up, 1 down | May 13, 2025 | $22.52M |
| Dec 31, 2024 | -$0.18 | -$0.22 | -$0.27 - -$0.18 | +19.39% | Beat | N/A | 6 | 1 up, 0 down | Mar 4, 2025 | $21.47M |
| Sep 30, 2024 | -$0.19 | -$0.27 | -$0.29 - -$0.24 | +29.63% | Beat | N/A | 6 | 0 up, 0 down | Nov 12, 2024 | $21.06M |
| Jun 30, 2024 | -$0.26 | -$0.30 | -$0.32 - -$0.26 | +13.33% | Beat | N/A | 6 | 0 up, 0 down | Aug 13, 2024 | $19.26M |
| Mar 31, 2024 | -$0.32 | -$0.32 | -$0.38 - -$0.26 | 0.00% | In line | N/A | 6 | 0 up, 0 down | May 8, 2024 | $18.12M |
| Dec 31, 2023 | -$0.23 | -$0.32 | -$0.36 - -$0.25 | +28.13% | Beat | N/A | 6 | 0 up, 0 down | Mar 5, 2024 | $18.01M |
| Sep 30, 2023 | -$0.28 | -$0.41 | -$0.44 - -$0.39 | +31.71% | Beat | N/A | 4 | 0 up, 0 down | Nov 6, 2023 | $16.43M |
| Jun 30, 2023 | -$0.36 | -$0.46 | -$0.49 - -$0.44 | +21.74% | Beat | N/A | 4 | 0 up, 0 down | Aug 8, 2023 | $16.51M |
| Mar 31, 2023 | -$0.41 | -$0.44 | -$0.50 - -$0.42 | +6.82% | Beat | N/A | 5 | 0 up, 0 down | May 4, 2023 | $14.47M |
| Dec 31, 2022 | -$0.45 | -$0.49 | -$0.51 - -$0.47 | +8.16% | Beat | N/A | 4 | 0 up, 0 down | Mar 2, 2023 | $12.79M |
| Sep 30, 2022 | -$0.48 | -$0.53 | -$0.54 - -$0.50 | +9.43% | Beat | N/A | 3 | 0 up, 0 down | Nov 8, 2022 | $11.16M |
| Jun 30, 2022 | -$0.52 | -$0.44 | -$0.46 - -$0.43 | -18.18% | Miss | N/A | 3 | 0 up, 0 down | Aug 11, 2022 | $10.20M |
| Mar 31, 2022 | -$0.47 | -$0.44 | -$0.49 - -$0.38 | -6.82% | Miss | N/A | 4 | 0 up, 0 down | May 12, 2022 | $11.37M |
| Dec 31, 2021 | -$0.44 | -$0.33 | -$0.34 - -$0.32 | -33.33% | Miss | N/A | 4 | N/A | Mar 10, 2022 | $11.00M |
| Sep 30, 2021 | -$0.34 | -$0.30 | -$0.32 - -$0.28 | -13.33% | Miss | N/A | 5 | N/A | Nov 10, 2021 | $10.34M |
| Jun 30, 2021 | -$0.48 | -$0.34 | -$0.51 - -$0.23 | -41.18% | Miss | N/A | 3 | N/A | Aug 12, 2021 | $12.63M |
| Mar 31, 2021 | -$32.73 | -$0.28 | N/A | N/A | N/A | N/A | N/A | N/A | Jun 3, 2021 | $11.22M |
| Dec 31, 2020 | -$0.17 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 24, 2021 | $10.75M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.66, after -$0.95 the year before. It was -$0.17 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.66 | N/A |
| Dec 31, 2024 | -$0.95 | N/A |
| Dec 31, 2023 | -$1.28 | N/A |
| Dec 31, 2022 | -$1.92 | N/A |
| Dec 31, 2021 | -$33.99 | N/A |
| Dec 31, 2020 | -$0.17 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,000 words across 10 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,968 | 10 | |
| 2026Q2 | Jun 30, 2026 | 8,277 | 11 | |
| 2026Q1 | Mar 31, 2026 | 6,368 | 12 | |
| 2025Q4 | Dec 31, 2025 | 7,210 | 8 | |
| 2025Q3 | Sep 30, 2025 | 7,091 | 10 | |
| 2025Q2 | Jun 30, 2025 | 8,217 | 11 | |
| 2025Q1 | Mar 31, 2025 | 6,178 | 10 | |
| 2024Q4 | Dec 31, 2024 | 6,297 | 11 |
2026Q3 Earnings Call
Opening remarks
Scott Schaper Vice President of Finance and Investor Relations Thank you, operator, and welcome to NeuroPace's Third Quarter 2026 Earnings Conference Call. Our agenda begins with Joel Becker, NeuroPace's Chief Executive Officer, who will summarize our recent performance and strategic progress, followed by a detailed financial review and outlook from Patrick Williams, our Chief Financial Officer. Following our prepared remarks, we will open the call for questions. Before we begin, I would like to remind you that certain statements made on today's call may constitute forward-looking statements within the meaning of federal securities laws. These statements include, among others, comments regarding our financial outlook for 2026 and preliminary expectations for 2027, our commercial strategy, our analyses of our third quarter commercial performance and our projections toward the effectiveness of future commercial execution, clinical and product development initiatives, regulatory matters, including potential indication expansion into idiopathic generalized epilepsy, or IGE, in pediatric patients 12 to 17 years of age, focal epilepsy, and our expectations regarding operating performance and profitability. Forward-looking statements are based on management's current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. A discussion of these risks and uncertainties can be found in today's press release and in our filings with the Securities and Exchange Commission, including our most recent Form 10-K and Form 10-Q. We undertake no obligation to update or revise any forward-looking statements, except as required by law. Unless otherwise noted, the financial results today reflect continuing operations and exclude our former SEEG distribution business, or DIXI Medical, in both the current and comparable prior periods. We will also discuss certain non-GAAP financial measures, including adjusted EBITDA. Reconciliations to the most directly comparable GAAP measures are included in today's earnings release, which is available on the Investor Relations section of our website. With that, I will now turn the call over to NeuroPace's Chief Executive Officer, Joel Becker. Joel?
Joel Becker CEO Thanks, Scott, and good afternoon, everyone. Our third quarter results fell short of our expectations, and I want to be direct about why and also what we're doing about it. I will begin with our results and the factors that affected performance, then provide updates on our IGE regulatory process, our pediatric focal epilepsy program intended for adolescents 12 to 17 years of age, and our product development initiatives. After that, Patrick will review our financial results and revised outlook. Total revenue in the third quarter was $23.1 million, including RNS System revenue of $22.9 million, representing RNS growth of approximately 1% year over year. This result fell well short of our expectations and does not reflect the growth the business has, and we believe we can deliver.
Frequently Asked Questions About NPCE
When is Neuropace's next earnings date?
Neuropace's next earnings report is expected for Mar 1, 2027.
Did NPCE beat earnings estimates last quarter?
Yes. Neuropace reported EPS of -$0.10 for the quarter ended Sep 30, 2026, above the -$0.14 estimate, a 28.57% surprise.
What EPS do analysts expect from NPCE next quarter?
The consensus EPS estimate for Neuropace for the quarter ending Dec 31, 2026 is -$0.09 from 12 analysts, with estimates from -$0.14 to -$0.04.
How often does NPCE beat earnings estimates?
Neuropace beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +18.74%.
NPCE pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts